Biocon hiring 300 scientists for new R&D complex in India

India's Biocon cut the ribbon on a new biologics R&D complex that will host a multi-disciplinary group of more than 300 scientists developing a new generation of "affordable" biologics. Nobel Laureate Kurt Wuthrich will helm the center, which is billed as the first of its kind in southeast Asia.

Biocon, which has experienced its own setbacks in drug development, has set its sights on expanding its work on novel therapies. Biocon chief Kiran Mazumdar-Shaw (photo), who built the company from scratch, has championed the country's drug development community. And she's been hiring an international group of investigators expert in molecular biology, biologics process sciences, formulation research and preclinical and clinical development. 

"I am enthralled with Biocon's research capabilities which are at par with international standards. I will keenly watch the outcome of innovation from this centre as I see a lot of promise in scientific talent here," said Wuthrich in a statement.

"We aspire to build a center of research excellence that will pursue an innovation-led effort to develop advanced yet affordable solutions for several debilitating diseases," says Mazumdar-Shaw. "It will epitomize Biocon's efforts to galvanize the best talent available both in India and from across the globe, and offer them an intellectually stimulating environment combined with an enabling ecosystem to conduct pathbreaking research for biopharmaceuticals."

- here's the press release

Special Report: Kiran Mazumdar-Shaw - The 25 most influential people in biopharma today